Under the loaded condition, TRPV4 siRNA-injected discs presented radiographic height loss ([-31.7, -7.75]), histomorphological damage ([0.300, 4.70]), and immunofluorescent suppression of autophagy ([1.61, 20.5]) and ECM metabolism ([-25.2, -6.41]) compared to control siRNA-injected discs at 56 days.<h4>Conclusions</h4>The TRPV4 could be a therapeutic target for intervertebral disc diseases via modulating autophagy. The gene discussed is TRPV4; the disease is intervertebral disk degenerative disorder.